Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.73 |
| ▸ | CTSK | P43235 | 10/20 | 0.73 |
| ▸ | CTSB | P07858 | 4/20 | 0.73 |
| ▸ | CTSL | P07711 | 2/20 | 0.73 |
| ▸ | AKT1 | P31749 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163823 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL30279703 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6163314 | 1.00 | CTSS (0.73) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL20669382 | 0.97 | CTSS (0.70) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3698861 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3698863 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL6353725 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL7029483 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL22928874 | 0.91 | REN (0.71) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL7283537 | 0.89 | MMP9 (0.69) | CTSSCTSKCTSBCTSLHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-112823036-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| CN-103826661-B | Novel binding agent-drug conjugates (ADCs) and uses thereof | 西雅图基因公司 | 2019-03-05 | — | — | CN | disclosed |
| EP-3184514-A1 | AUTOPHAGY INHIBITORS | Deutsches Krebsforschungszentrum (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-08-13 | — | — | US | disclosed |
| EP-1973887-B1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | IMMUPHARMA FRANCE SA (FR) | 2012-09-19 | — | — | EP | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | OR10J3, CCR3, GPR3 | CTSS 4685/4885CTSK 4641/4885CTSB 4526/4885 |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CTSS 177/4885CTSK 286/4885CTSB 79/4885 |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | NR4A3, ORC3, NTSR1 | CTSS 3296/4885CTSK 3687/4885CTSB 3329/4885 |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CTSS 2304/4885CTSK 2261/4885CTSB 2060/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | CTSS 2780/4885CTSK 2569/4885CTSB 2200/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CTSS 2304/4885CTSK 2261/4885CTSB 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.